SCHOLAR ROCK HOLDING CORPORATION Operating Lease, Right-of-Use Asset, Amortization Expense
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.52M, a 17.57% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.54M, a 24.09% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.39M, a 16.39% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.34M, a 17.79% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for fiscal 2025 was $5.26M, a 0.73% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for fiscal 2024 was $5.22M, a 26.69% decline from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for fiscal 2023 was $7.13M, a 3.29% increase from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, right-of-use asset, amortization expense for fiscal 2022 was $6.90M, a 7.85% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.06M 10-Q · filed 2026-08-06 | $4.44M derived: sum of 3 quarters · filed 2026-08-06 | $5.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.54M 10-Q · filed 2026-05-07 | $2.92M derived: sum of 2 quarters · filed 2026-05-07 | $4.27M derived: sum of 3 quarters · filed 2026-05-07 | $5.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.73M derived: sum of 2 quarters · filed 2026-03-03 | $4.02M derived: sum of 3 quarters · filed 2026-08-06 | $5.26M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.64M derived: sum of 2 quarters · filed 2026-08-06 | $3.88M 10-Q · filed 2025-11-14 | $5.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.53M 10-Q · filed 2026-08-06 | $3.72M derived: sum of 3 quarters · filed 2026-08-06 | $4.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.24M 10-Q · filed 2026-05-07 | $2.43M derived: sum of 2 quarters · filed 2026-05-07 | $3.57M derived: sum of 3 quarters · filed 2026-05-07 | $4.85M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.33M derived: sum of 2 quarters · filed 2026-03-03 | $3.61M derived: sum of 3 quarters · filed 2026-03-03 | $5.22M 10-K · filed 2026-03-03 |
| 2024-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.42M derived: sum of 2 quarters · filed 2025-11-14 | $4.03M 10-Q · filed 2025-11-14 | $5.61M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.89M 10-Q · filed 2025-08-06 | $4.47M derived: sum of 3 quarters · filed 2025-08-06 | $6.36M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.61M 10-Q · filed 2025-05-14 | $3.19M derived: sum of 2 quarters · filed 2025-05-14 | $5.08M derived: sum of 3 quarters · filed 2025-05-14 | $6.93M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.47M derived: sum of 2 quarters · filed 2025-02-27 | $5.31M derived: sum of 3 quarters · filed 2025-02-27 | $7.13M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.73M derived: sum of 2 quarters · filed 2024-11-12 | $5.55M 10-Q · filed 2024-11-12 | $7.32M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.66M 10-Q · filed 2024-08-08 | $5.43M derived: sum of 3 quarters · filed 2024-08-08 | $7.17M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.81M 10-Q · filed 2024-05-07 | $3.59M derived: sum of 2 quarters · filed 2024-05-07 | $5.33M derived: sum of 3 quarters · filed 2024-05-07 | $7.04M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.52M derived: sum of 2 quarters · filed 2024-03-19 | $5.22M derived: sum of 3 quarters · filed 2024-03-19 | $6.90M 10-K · filed 2024-03-19 |
| 2022-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.45M derived: sum of 2 quarters · filed 2023-11-07 | $5.12M 10-Q · filed 2023-11-07 | $6.76M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.38M 10-Q · filed 2023-08-09 | $5.02M derived: sum of 3 quarters · filed 2023-08-09 | $6.67M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.68M 10-Q · filed 2023-05-09 | $3.32M derived: sum of 2 quarters · filed 2023-05-09 | $4.96M derived: sum of 3 quarters · filed 2023-05-09 | $6.54M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $3.29M derived: sum of 2 quarters · filed 2023-03-07 | $4.86M derived: sum of 3 quarters · filed 2023-03-07 | $6.40M 10-K · filed 2023-03-07 |
| 2021-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $3.22M derived: sum of 2 quarters · filed 2022-11-14 | $4.75M 10-Q · filed 2022-11-14 | $6.34M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.11M 10-Q · filed 2022-08-08 | $4.70M derived: sum of 3 quarters · filed 2022-08-08 | $4.96M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.54M 10-Q · filed 2022-05-16 | $3.13M derived: sum of 2 quarters · filed 2022-05-16 | $3.39M derived: sum of 3 quarters · filed 2022-05-16 | $3.66M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $1.86M derived: sum of 2 quarters · filed 2022-03-07 | $2.12M derived: sum of 3 quarters · filed 2022-03-07 | $2.38M 10-K · filed 2022-03-07 |
| 2020-09-30 | $268.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $532.00K derived: sum of 2 quarters · filed 2021-11-09 | $791.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $264.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $523.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $259.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $997.00K 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |